C Champions Oncology Inc
C
Fermé
SecteurSoins de santé
6.26 1.29
Résumé
Variation du prix de l'action
24h
Min
5.45
Max
6.41
Revenu | -514K -278K |
|---|---|
Ventes | 1.5M 17M |
P/E Moyenne du Secteur | 35.118 50.958 |
BPA | -0.02 |
Marge bénéficiaire | -1.679 |
Employés | 213 |
EBITDA | -508K 104K |
Prochains Résultats | 22 juil. 2026 |
|---|
Capitalisation Boursière | 3.9M 87M |
|---|---|
Ouverture précédente | 4.97 |
Clôture précédente | 6.26 |
Sentiment de l'Actualité
By Acuity
100%
0%
323 / 342 Classement par Healthcare
Champions Oncology Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.